Preview

 Пульмонология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Только для подписчиков

Генно-инженерно-биологические препараты в терапии бронхиальной астмы: современные достижения

https://doi.org/10.18093/0869-0189-2018-28-5-584-601

Полный текст:

Аннотация

Согласно международным статистическим данным, в современной популяции пациентов с бронхиальной астмой (БА) отмечается тенденция по увеличению резистентности к таким стандартным инструментам базисной фармакотерапии, как ингаляционные глюкокортикостероиды, антилейкотриеновые препараты и антииммуноглобулин (Ig)-E-препараты, что указывает на их недостаточную эффективность. Определенное значение в характере ответа на терапию имеет фенотип заболевания, подразумевающий вовлеченность определенных биомаркеров в патогенез воспалительного процесса на уровне бронхов. Прямое воздействие на модуляторы и медиаторы воспаления и бронхоконстрикции, которое могут обеспечить генно-инженерно-биологические препараты (ГИБП), является одним из наиболее перспективных направлений современной фармакотерапии БА, особенно в отношении популяции пациентов с тяжелой БА, резистентной к стандартным методам лечения. В статье приведен сравнительный анализ эффективности и безопасности, согласно данным рандомизированных контролируемых исследований (РКИ), основных групп ГИБП, существующих на сегодняшний день – препараты моноклональных антител к IgE, препараты моноклональных антител к интерлейкинам (IL)-4 / IL-13, IL-5 и препараты антагонистов к рецепторам простагландина-D2, По данным РКИ, омализумаб сохраняет свои лидирующие позиции в ряду активно развивающихся ГИБП, при этом в ряду новых представителей ГИБП обнаружены доказательства эффективности и безопасности их применения, позволяющие им занять свою нишу в терапевтическом арсенале врача-пульмонолога, в частности для лечения пациентов с тяжелой эозинофильной БА.

Об авторах

С. К. Зырянов
Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов» (Медицинский институт); Государственное бюджетное учреждение города Москвы «Городская клиническая больница № 24 Департамента здравоохранения города Москвы»
Россия

Зырянов Сергей Кенсаринович – доктор медицинских наук, профессор, заведующий кафедрой общей и клинической фармакологии Федерального государственного автономного образовательного учреждения высшего образования «Российский университет дружбы народов», заместитель главного врача Государственного бюджетного учреждения здравоохранения «Городская клиническая больница № 24 Департамента здравоохранения города Москвы»

117198, Москва, ул. Миклухо-Маклая, 6, 

127015, Москва, Писцовая, 10



О. И. Бутранова
Федеральное государственное автономное образовательное учреждение высшего образования «Российский университет дружбы народов» (Медицинский институт); Государственное бюджетное учреждение города Москвы «Городская клиническая больница № 24 Департамента здравоохранения города Москвы»
Россия

Бутранова Ольга Игоревна – кандидат медицинских наук, ассистент кафедры общей и клинической фармакологии Медицинского института Федерального государственного автономного образовательного учреждения высшего образования «Российский университет дружбы народов», заместитель главного врача Государственного бюджетного учреждения здравоохранения «Городская клиническая больница № 24 Департамента здравоохранения города Москвы»

117198, Москва, ул. Миклухо-Маклая, 6, 

127015, Москва, Писцовая, 10



Список литературы

1. Demoly P., Annunziata K., Gubba E., Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur. Respir. Rev. 2012; 21 (123): 66–74. DOI: 10.1183/09059180.00008111.

2. Desai M., Oppenheimer J. Elucidating asthma phenotypes and endotypes: progress towards personalized medicine. Ann. Allergy Asthma Immunol. 2016; 116 (5): 394–401. DOI: 10.1016/j.anai.2015.12.024.

3. Wenzel S.E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 2012; 18 (5): 716–725. DOI: 10.1038/nm.2678.

4. Menzella F., Galeone C., Bertolini F. et al. Innovative treatments for severe refractory asthma: how to choose the right option for the right patient? J. Asthma Allergy. 2017; (10): 237–247. DOI: 10.2147/JAA.S144100.

5. Oettgen H.C. Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J. Allergy Clin. Immunol. 2016; 137 (6): 1631–1645. DOI: 10.1016/j.jaci.2016.04.009.

6. Bousquet J., Cabrera P., Berkman N. et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005; 60 (3): 302–308. DOI: 10.1111/j.1398-9995.2004.00770.x.

7. Humbert M., Beasley R., Ayres J. et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005; 60 (3): 309–316. DOI: 10.1111/j.1398-9995.2004.00772.x.

8. Brusselle G., Michils A., Louis R. et al. Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir. Med. 2009; 103 (11):1633–1642. DOI: 10.1016/j.rmed.2009.06.014.

9. Braunstahl G.J., Chen C.W., Maykut R. et al. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. Respir. Med. 2013; 107 (8) 1141–1151. DOI: 10.1016/j.rmed.2013.04.017.

10. Milgrom H., Berger W., Nayak A. et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001; 108 (2): e36. DOI: 10.1542/peds.108.2.e36.

11. Busse W.W., Morgan W.J., Gergen P.J. et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N. Engl. J. Med. 2011; 364 (11): 1005–1015. DOI: 10.1056/NEJMoa1009705.

12. Brodlie M., McKean M.C., Moss S., Spencer D.A. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch. Dis. Child. 2012; 97 (7): 604–609. DOI: 10.1136/archdischild-2011-301570.

13. Odajima H., Ebisawa M., Nagakura T. et al. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy. Allergol. Int. 2015; 64 (4): 364–370. DOI: 10.1016/j.alit.2015.05.006.

14. Odajima H., Ebisawa M., Nagakura T. et al. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma. Allergol. Int. 2017; 66 (1): 106–115. DOI: 10.1016/j.alit.2016.06.004.

15. Deschildre A., Marguet C., Salleron J. et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur. Respir. J. 2013; 42 (5): 1224–1233. DOI: 10.1183/09031936.00149812.

16. Deschildre A., Marguet C., Langlois C. et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur. Respir. J. 2015; 46 (3): 856–859. DOI: 10.1183/09031936.00008115.

17. Campbell J.M., Wofford J.D., Knutsen A.P. Omalizumab treatment in children 6 to 18 years old with severe asthma at a children’s medical center. Pediatr. Allergy Immunol. Pulmonol. 2008; 21 (3): 123–148. DOI: 10.1089/pai.2008.0502.

18. Corren J., Kavati A., Ortiz B. et al. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: a systematic literature review. Allergy Asthma Proc. 2017; 38 (4): 250–263. DOI: 10.2500/aap.2017.38.4067.

19. Lanier B., Bridges T., Kulus M. et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J. Allergy Clin. Immunol. 2009; 124 (6): 1210–1216. DOI: 10.1016/j.jaci.2009.09.021.

20. Steiss J.O., Schmidt A., Nährlich L. et al. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents. Allergy Asthma Proc. 2012; 33 (1): 77–81. DOI: 10.2500/aap.2012.33.3500.

21. Mansur A., Srivastava S., Mitchell V. et al. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: study of efficacy and safety. Respir. Med. 2017; 124: 36–43. DOI: 10.1016/j.rmed.2017.01.008.

22. Long A., Rahmaoui A., Rothman K.J. et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J. Allergy Clin. Immunol. 2014; 134 (3): 560–567. DOI: 10.1016/j.jaci.2014.02.007.

23. Harris J.M., Maciuca R., Bradley M.S. et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir. Res. 2016; (17): 29. DOI: 10.1186/s12931-016-0347-2.

24. Hanania N.A., Alpan O., Hamilos D.L. et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann. Intern. Med. 2011; 154 (9): 573–582. DOI: 10.7326/0003-4819-154-9-201105030-00002.

25. Gauvreau G.M., Arm J.P., Boulet L.P. et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J. Allergy Clin. Immunol. 2016; 138 (4): 1051-1059. DOI: 10.1016/j.jaci.2016.02.027.

26. Hanania N.A., Noonan M., Corren J. et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015; 70 (8) 748–756. DOI: 10.1136/thoraxjnl-2014-206719.

27. Scheerens H., Arron J.R., Zheng Y. et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin. Exp. Allergy. 2014; 44 (1): 38–46. DOI: 10.1111/cea.12220.

28. Hanania N.A, Korenblat P., Chapman K.R. et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir. Med. 2016; 4 (10): 781–796. DOI: 10.1016/S2213-2600(16)30265-X.

29. Panettieri R.A. Jr, Wang M., Braddock M. et al. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. Immunotherapy. 2018; 10 (6): 473–490. DOI: 10.2217/imt-2017-0191.

30. Simpson E.L., Flohr C., Eichenfield L.F. et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J. Am. Acad. Dermatol. 2018; 78 (5): 863–871. DOI: 10.1016/j.jaad.2018.01.017.

31. Slager R.E., Otulana B.A., Hawkins G.A. et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti–IL-4 receptor α antagonist. J. Allergy Clin. Immunol. 2012; 130 (2): 516–522. DOI: 10.1016/j.jaci.2012.03.030.

32. Shirley M. Dupilumab: First Global Approval. Drugs. 2017; 77 (10): 1115–1121. DOI: 10.1007/s40265-017-0768-3.

33. Gooderham M.J., Hong H.C., Eshtiaghi P., Papp K.A. Dupilumab: a review of its use in the treatment of atopic dermatitis. J. Am. Acad. Dermatol. 2018; 78 (3, Suppl.1): S28–S36. DOI: 10.1016/j.jaad.2017.12.022.

34. Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9842): 651–659. DOI: 10.1016/S0140-6736(12)60988-X.

35. Varricchi G., Senna G., Loffredo S. et al. Reslizumab and eosinophilic asthma: one step closer to precision medicine? Front Immunol. 2017; (8): 242. DOI: 10.3389/fimmu.2017.00242.

36. Garcia G., Taille C., Laveneziana P. et al. Anti-interleukin-5 therapy in severe asthma. Eur. Respir. Rev. 2013; 22 (129): 251–257. DOI: 10.1183/09059180.00004013.

37. Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 2014; 371 (13): 1198–207. DOI: 10.1056/NEJMoa1403290.

38. Varricchi G., Bagnasco D., Ferrando M. et al. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther. Adv. Respir. Dis. 2017; 11 (1): 40–45. DOI: 10.1177/1753465816673303.

39. Menzies-Gow A., Flood-Page P., Sehmi R. et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J. Allergy Clin. Immunol. 2003; 111 (4): 714–719. DOI: 10.1067/mai.2003.1382.

40. Flood-Page P.T., Menzies-Gow A.N., Kay A.B., Robinson D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 2003; 167 (2): 199–204. DOI: 10.1164/rccm.200208-789OC.

41. Flood-Page P., Swenson C., Faiferman I. et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med. 2007; 176 (11): 1062–1071. DOI: 10.1164/rccm.200701-085OC.

42. Haldar P., Brightling C. E., Hargadon B. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 2009; 360 (10): 973–984. DOI: 10.1056/NEJMoa0808991.

43. Nair P., Pizzichini M.M., Kjarsgaard M. et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 2009; 360 (10): 985–993. DOI: 10.1056/NEJMoa0805435.

44. Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9842): 651–659. DOI: 10.1016/S0140-6736(12)60988-X.

45. Bel E.H., Wenzel S.E., Thompson P.J. et al. SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 2014; 371 (13): 1189–1197. DOI: 10.1056/NEJMoa1403291.

46. Haldar P., Brightling C.E., Singapuri A. et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J. Allergy Clin. Immunol. 2014; 133 (3): 921–923. DOI: 10.1016/j.jaci.2013.11.026.

47. Lugogo N., Domingo C., Chanez P. et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin. Ther. 2016; 38 (9): 2058–2070. DOI: 10.1016/j.clinthera.2016.07.010.

48. Chupp G.L., Bradford E.S., Albers F.C. et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir. Med. 2017; 5 (5): 390–400. DOI: 10.1016/S2213-2600(17)30125-X.

49. Yancey S.W., Ortega H.G., Keene O.N. et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. J. Allergy Clin. Immunol. 2017; 139 (4): 1167–1175. DOI: 10.1016/j.jaci.2016.08.008.

50. Castro M., Mathur S., Hargreave F. et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 2011; 184 (10): 1125–1132. DOI: 10.1164/rccm.201103-0396OC.

51. Castro M., Zangrilli J., Wechsler M.E. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 2015; 3 (5): 355–366. DOI: 10.1016/S2213-2600(15)00042-9.

52. Bjermer L., Lemiere C., Maspero J. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016; 150 (4): 789–798. DOI: 10.1016/j.chest.2016.03.032.

53. Corren J., Weinstein S., Janka L. et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016; 150 (4): 799–810. DOI: 10.1016/j.chest.2016.03.018.

54. Pelaia C., Vatrella A., Bruni A. et al. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Des. Devel. Ther. 2018; 12: 619–628. DOI: 10.2147/DDDT.S155307.

55. Busse W.W., Katial R., Gossage D. et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J. Allergy Clin. Immunol. 2010; 125 (6):1237–1244 e2. DOI: 10.1016/j.jaci.2010.04.005.

56. Laviolette M., Gossage D.L., Gauvreau G. et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J. Allergy Clin. Immunol. 2013; 132 (5): 1086–1096 e5. DOI: 10.1016/j.jaci.2013.05.020.

57. Park H.S., Kim M.K., Imai N. et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. Int. Arch. Allergy Immunol. 2016; 169 (3): 135–145. DOI: 10.1159/000444799.

58. Castro M., Wenzel S.E., Bleecker E.R. et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir. Med. 2014; 2 (11): 879–890. DOI: 10.1016/S2213-2600(14)70201-2.

59. Nowak R.M., Parker J.M., Silverman R.A. et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Am. J. Emerg. Med. 2015; 33 (1): 14–20. DOI: 10.1016/j.ajem.2014.09.036.

60. Bleecker E.R., FitzGerald J.M., Chanez P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2115–2127. DOI: 10.1016/S0140-6736(16)31324-1.

61. FitzGerald J.M., Bleecker E.R., Nair P. et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2128–2141. DOI: 10.1016/S0140-6736(16)31322-8.

62. Nair P., Wenzel S., Rabe K.F. et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N. Engl. J. Med. 2017; 376 (25): 2448–2458. DOI: 10.1056/NEJMoa1703501.

63. Ferguson G.T., FitzGerald J.M., Bleecker E.R. et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 2017; 5 (7): 568–576. DOI: 10.1016/S2213-2600(17)30190-X.

64. Matera M.G., Calzetta L., Rinaldi B., Cazzola M. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. Expert Opin. Drug Metab. Toxicol. 2017; 13 (9): 1007–1013. DOI: 10.1080/17425255.2017.1359253.

65. Liu T., Wang F., Wang G. et al. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials. Front Med. 2018; 12 (3): 340–349. DOI: 10.1007/s11684-017-0565-0.

66. FitzGerald J.M., Bleecker E.R., Menzies-Gow A. et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir. Med. 2018; 6 (1): 51–64. DOI: 10.1016/S2213-2600(17)30344-2.

67. Chipps B.E., Newbold P., Hirsch I. et al. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann. Allergy Asthma Immunol. 2018; 120 (5): 504–511. DOI: 10.1016/j.anai.2018.01.030.

68. Albers F.C., Müllerová H., Gunsoy N.B. et al. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J. Asthma. 2017; 55 (2): 152–160. DOI: 10.1080/02770903.2017.1322611.

69. Albers F.C., Liu M.C., Chipps B.E. et al. Efficacy and safety of mepolizumab in uncontrolled patients with severe eosinophilic asthma following a switch from omalizumab (OSMO study): asthma control, quality of life and lung function outcomes. J. Allergy Clin. Immunol. 2018; 141 (2): AB408. DOI: 10.1016/j.jaci.2017.12.964.

70. Erpenbeck V.J., Popov T.A., Miller D. et al. The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma. Pulm. Pharmacol. Ther. 2016; (39): 54–63. DOI: 10.1016/j.pupt.2016.06.005.

71. Gonem S., Berair R., Singapuri A. et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: single-centre, randomised, double-blind, parallel-group, placebo controlled trial. Lancet Respir. Med. 2016; 4 (9): 699–707. DOI: 10.1016/S2213-2600(16)30179-5.

72. Bateman E.D., Guerreros A.G., Brockhaus F. et al. Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. Eur. Respir. J. 2017: 50 (2): pii: 1700670. DOI: 10.1183/13993003.00670-2017.


Для цитирования:


Зырянов С.К., Бутранова О.И. Генно-инженерно-биологические препараты в терапии бронхиальной астмы: современные достижения.  Пульмонология. 2018;28(5):584-601. https://doi.org/10.18093/0869-0189-2018-28-5-584-601

For citation:


Zyryanov S.K., Butranova O.I. Genetically engineered drugs for treatment of bronchial asthma: recent achievements. Russian Pulmonology. 2018;28(5):584-601. (In Russ.) https://doi.org/10.18093/0869-0189-2018-28-5-584-601

Просмотров: 811


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)